Back

Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Bleeding and antiplatelet strategies in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Doctor Francesco Bruno

A.O.U. Citta Della Salute E Della Scienza Di Torino Molinette, Turin (Italy)

Photo
Doctor Florian A Wenzl

University of Zurich, Zurich (Switzerland)

7 More presentations in this session

Presentation thumbnail
Temporal trends in major bleeding after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction from 2003 to 2017: the Western Denmark Heart Registry
Doctor P. Thrane (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Thirty days clinical outcomes following stent implantation with aspirin-free prasugrel monotherapy in non-ST segment elevation myocardial infarction. Interim report from ASET-Japan pilot study
Doctor K. Miyashita (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Ticagrelor vs. clopidogrel in ST elevation myocardial infarction patients with hemoglobin > 160
Doctor T. Gu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Association of P2Y12 inhibitor pretreatment strategy with short and long term ischemic and bleeding outcomes in NSTE-ACS patients
Doctor K. Keskin (Hakkari, TR) Associate Professor A. Calik (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Differential prognostic significance of platelet reactivity based on ischemic risk after percutaneous coronary intervention
Assistant Professor K. Jeon (Seongnam, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Bleeding and antiplatelet strategies in acute coronary syndromes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
thumbnail
Congress Presentation
Abbreviated versus standard dual antiplatelet therapy time after PCI in high bleeding risk patients with acute coronary syndrome - a report from the SWEDEHEART registry
thumbnail
Congress Presentation
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources